SK16852001A3 - Tiazolové deriváty a farmaceutické kompozície ich obsahujúce - Google Patents

Tiazolové deriváty a farmaceutické kompozície ich obsahujúce Download PDF

Info

Publication number: SK16852001A3
Authority: SK; Slovakia
Prior art keywords: thiophen; benzo; dihydroimidazo; formula; compound
Prior art date: 1999-05-21

Application number

SK1685-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Paul Andrew Brough

Sharon Crawford Cheetham

Frank Kerrigan

John Paul Watts

Original Assignee

Knoll Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-21

Filing date

2000-05-11

Publication date

2002-05-09

2000-05-11 Application filed by Knoll Gmbh filed Critical Knoll Gmbh

2002-05-09 Publication of SK16852001A3 publication Critical patent/SK16852001A3/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 10
150000001875 compounds Chemical class 0.000 claims abstract description 293
239000000203 mixture Substances 0.000 claims abstract description 189
238000000034 method Methods 0.000 claims abstract description 50
238000011282 treatment Methods 0.000 claims abstract description 24
208000011117 substance-related disease Diseases 0.000 claims abstract description 16
208000008589 Obesity Diseases 0.000 claims abstract description 15
235000020824 obesity Nutrition 0.000 claims abstract description 15
206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 12
208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
206010010904 Convulsion Diseases 0.000 claims abstract description 9
208000030814 Eating disease Diseases 0.000 claims abstract description 9
208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 9
208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 9
208000012902 Nervous system disease Diseases 0.000 claims abstract description 9
208000025966 Neurological disease Diseases 0.000 claims abstract description 9
208000006011 Stroke Diseases 0.000 claims abstract description 9
230000036506 anxiety Effects 0.000 claims abstract description 9
208000010877 cognitive disease Diseases 0.000 claims abstract description 9
235000014632 disordered eating Nutrition 0.000 claims abstract description 9
206010015037 epilepsy Diseases 0.000 claims abstract description 9
201000001421 hyperglycemia Diseases 0.000 claims abstract description 9
206010013654 Drug abuse Diseases 0.000 claims abstract description 8
208000028017 Psychotic disease Diseases 0.000 claims abstract description 8
206010041250 Social phobia Diseases 0.000 claims abstract description 8
206010043118 Tardive Dyskinesia Diseases 0.000 claims abstract description 8
208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 8
208000022531 anorexia Diseases 0.000 claims abstract description 8
230000006378 damage Effects 0.000 claims abstract description 8
206010061428 decreased appetite Diseases 0.000 claims abstract description 8
206010013663 drug dependence Diseases 0.000 claims abstract description 8
230000000926 neurological effect Effects 0.000 claims abstract description 8
201000000980 schizophrenia Diseases 0.000 claims abstract description 8
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
208000032841 Bulimia Diseases 0.000 claims abstract description 7
206010019196 Head injury Diseases 0.000 claims abstract description 7
208000032843 Hemorrhage Diseases 0.000 claims abstract description 7
206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 6
208000020401 Depressive disease Diseases 0.000 claims abstract description 6
206010033664 Panic attack Diseases 0.000 claims abstract description 6
208000019906 panic disease Diseases 0.000 claims abstract description 6
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 5
208000014679 binge eating disease Diseases 0.000 claims abstract 2
239000002904 solvent Substances 0.000 claims description 194
-1 carbamoylmethyl Chemical group 0.000 claims description 172
125000004432 carbon atom Chemical group C* 0.000 claims description 138
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 126
125000000217 alkyl group Chemical group 0.000 claims description 103
229910052736 halogen Inorganic materials 0.000 claims description 53
125000005843 halogen group Chemical group 0.000 claims description 50
150000002367 halogens Chemical class 0.000 claims description 47
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
238000009835 boiling Methods 0.000 claims description 35
150000003839 salts Chemical class 0.000 claims description 28
238000006243 chemical reaction Methods 0.000 claims description 24
125000003545 alkoxy group Chemical group 0.000 claims description 23
238000010992 reflux Methods 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 21
125000003342 alkenyl group Chemical group 0.000 claims description 20
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 18
LVOMAJDUIUCBRF-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=O)=CSC2=C1 LVOMAJDUIUCBRF-UHFFFAOYSA-N 0.000 claims description 15
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 14
125000004414 alkyl thio group Chemical group 0.000 claims description 14
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 13
125000005036 alkoxyphenyl group Chemical group 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
201000006474 Brain Ischemia Diseases 0.000 claims description 10
125000001589 carboacyl group Chemical group 0.000 claims description 10
206010008118 cerebral infarction Diseases 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 claims description 9
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 9
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
229910052799 carbon Inorganic materials 0.000 claims description 9
239000003638 chemical reducing agent Substances 0.000 claims description 9
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
NJXYNQBZHYKKOI-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)CO)=CSC2=C1 NJXYNQBZHYKKOI-UHFFFAOYSA-N 0.000 claims description 8
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
125000005605 benzo group Chemical group 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 8
125000005016 hydroxyalkynyl group Chemical group 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
230000004584 weight gain Effects 0.000 claims description 8
235000019786 weight gain Nutrition 0.000 claims description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
125000000304 alkynyl group Chemical group 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 7
231100000867 compulsive behavior Toxicity 0.000 claims description 7
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 7
230000000391 smoking effect Effects 0.000 claims description 7
229910052717 sulfur Inorganic materials 0.000 claims description 7
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
125000005110 aryl thio group Chemical group 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
230000002526 effect on cardiovascular system Effects 0.000 claims description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
125000002524 organometallic group Chemical group 0.000 claims description 6
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 6
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
DQVCINHQPHPGMO-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]ethanone Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(=O)C)=CSC2=C1 DQVCINHQPHPGMO-UHFFFAOYSA-N 0.000 claims description 5
FQICMVANHBIPOM-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(propan-2-yloxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COC(C)C)=CSC2=C1 FQICMVANHBIPOM-UHFFFAOYSA-N 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
ZJQGNICAUJOFLW-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]pent-4-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(CCC=C)O)=CSC2=C1 ZJQGNICAUJOFLW-UHFFFAOYSA-N 0.000 claims description 4
YELGWSUWLGBWTC-UHFFFAOYSA-N 2-bromo-3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 YELGWSUWLGBWTC-UHFFFAOYSA-N 0.000 claims description 4
ATYGHWSFFZRFKU-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)Br)=CSC2=C1 ATYGHWSFFZRFKU-UHFFFAOYSA-N 0.000 claims description 4
MGZVBYIELZDRPA-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=CC=C2C(C3=C(SC4=NCCCN43)Br)=CSC2=C1 MGZVBYIELZDRPA-UHFFFAOYSA-N 0.000 claims description 4
NFGPFCPZPMBJMV-UHFFFAOYSA-N 3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(C=O)SC2=NCCN12 NFGPFCPZPMBJMV-UHFFFAOYSA-N 0.000 claims description 4
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
NUUBQIMKZKAJIL-UHFFFAOYSA-N S1C2=C(C(=C1)C=1N3C(SC1C=NO)=NCC3)C=CC=C2 Chemical compound S1C2=C(C(=C1)C=1N3C(SC1C=NO)=NCC3)C=CC=C2 NUUBQIMKZKAJIL-UHFFFAOYSA-N 0.000 claims description 4
YBWSXPROZCISEK-UHFFFAOYSA-N [3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=C(Cl)C=C2C(C3=C(SC4=NCCN43)CO)=CSC2=C1 YBWSXPROZCISEK-UHFFFAOYSA-N 0.000 claims description 4
125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
125000005018 aryl alkenyl group Chemical group 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 4
239000003723 serotonin 1A agonist Substances 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
230000004580 weight loss Effects 0.000 claims description 4
QHXBNXGJZCQEGL-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-2-methylprop-2-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C(=C)C)=CSC2=C1 QHXBNXGJZCQEGL-UHFFFAOYSA-N 0.000 claims description 3
BMRHBTYHKWSRIW-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-3-methylbutan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CC(C)C)=CSC2=C1 BMRHBTYHKWSRIW-UHFFFAOYSA-N 0.000 claims description 3
BXBNMUMGPWXSBZ-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(CC=C)O)=CSC2=C1 BXBNMUMGPWXSBZ-UHFFFAOYSA-N 0.000 claims description 3
VDFKOANEFHDZCN-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(ethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COCC)=CSC2=C1 VDFKOANEFHDZCN-UHFFFAOYSA-N 0.000 claims description 3
CDXCLKPOPFFADV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(methoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)COC)=CSC2=C1 CDXCLKPOPFFADV-UHFFFAOYSA-N 0.000 claims description 3
RILVHTAZUWRQBD-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-chloro-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)Cl)=CSC2=C1 RILVHTAZUWRQBD-UHFFFAOYSA-N 0.000 claims description 3
QLDFDZWVUGXNPJ-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-ethenyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=C)=CSC2=C1 QLDFDZWVUGXNPJ-UHFFFAOYSA-N 0.000 claims description 3
LCLXKOYOAYQQNR-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-prop-1-en-2-yl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(=C)C)=CSC2=C1 LCLXKOYOAYQQNR-UHFFFAOYSA-N 0.000 claims description 3
ZCRXSSGNFXOREU-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-n,n-dimethyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-amine Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)N(C)C)=CSC2=C1 ZCRXSSGNFXOREU-UHFFFAOYSA-N 0.000 claims description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
LDZUITFMCBWNAT-UHFFFAOYSA-N [3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)CO)=COC2=C1 LDZUITFMCBWNAT-UHFFFAOYSA-N 0.000 claims description 3
YXWJCIUFDHSOSG-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-(2-methoxyphenyl)methanol Chemical compound COC1=CC=CC=C1C(O)C(S1)=C(C=2C3=CC=CC=C3SC=2)N2C1=NCC2 YXWJCIUFDHSOSG-UHFFFAOYSA-N 0.000 claims description 3
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 3
230000036528 appetite Effects 0.000 claims description 3
235000019789 appetite Nutrition 0.000 claims description 3
239000003054 catalyst Substances 0.000 claims description 3
235000019253 formic acid Nutrition 0.000 claims description 3
238000002955 isolation Methods 0.000 claims description 3
229940126403 monoamine reuptake inhibitor Drugs 0.000 claims description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
125000005504 styryl group Chemical group 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
GVXWRWHEHPYBON-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]ethanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C)=CSC2=C1 GVXWRWHEHPYBON-UHFFFAOYSA-N 0.000 claims description 2
FQGRDDBPUOVQKN-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]pentan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CCCC)=CSC2=C1 FQGRDDBPUOVQKN-UHFFFAOYSA-N 0.000 claims description 2
SNZQXQLEUUCMHL-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]prop-2-yn-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C#C)O)=CSC2=C1 SNZQXQLEUUCMHL-UHFFFAOYSA-N 0.000 claims description 2
ANPWDQQMZFHAIP-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]propan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CC)=CSC2=C1 ANPWDQQMZFHAIP-UHFFFAOYSA-N 0.000 claims description 2
ACCFGYMZBUOSOA-UHFFFAOYSA-N 2-bromo-3-(7-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound COC1=CC=CC2=C1SC=C2C1=C(Br)SC2=NCCN12 ACCFGYMZBUOSOA-UHFFFAOYSA-N 0.000 claims description 2
KNCWSSXTPRMWAS-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(2-phenylethenyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N=1CCN(C=2C=3C4=CC=CC=C4SC=3)C=1SC=2C=CC1=CC=CC=C1 KNCWSSXTPRMWAS-UHFFFAOYSA-N 0.000 claims description 2
XXJCNPBBXGUYKE-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-iodo-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)I)=CSC2=C1 XXJCNPBBXGUYKE-UHFFFAOYSA-N 0.000 claims description 2
SDJCTHBPRIXHBO-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-phenylsulfanyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N=1CCN(C=2C=3C4=CC=CC=C4SC=3)C=1SC=2SC1=CC=CC=C1 SDJCTHBPRIXHBO-UHFFFAOYSA-N 0.000 claims description 2
TWZWVQFMKXUFBH-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbonitrile Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C#N)=CSC2=C1 TWZWVQFMKXUFBH-UHFFFAOYSA-N 0.000 claims description 2
JSSBZHNLEZWWCQ-UHFFFAOYSA-N 4-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-2-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=CC(O)C)=CSC2=C1 JSSBZHNLEZWWCQ-UHFFFAOYSA-N 0.000 claims description 2
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
201000005569 Gout Diseases 0.000 claims description 2
208000034991 Hiatal Hernia Diseases 0.000 claims description 2
206010020028 Hiatus hernia Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
201000001880 Sexual dysfunction Diseases 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
208000021017 Weight Gain Diseases 0.000 claims description 2
239000003377 acid catalyst Substances 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
238000002651 drug therapy Methods 0.000 claims description 2
230000004064 dysfunction Effects 0.000 claims description 2
210000003238 esophagus Anatomy 0.000 claims description 2
150000004820 halides Chemical class 0.000 claims description 2
230000002140 halogenating effect Effects 0.000 claims description 2
230000007062 hydrolysis Effects 0.000 claims description 2
238000006460 hydrolysis reaction Methods 0.000 claims description 2
125000005350 hydroxycycloalkyl group Chemical group 0.000 claims description 2
208000013403 hyperactivity Diseases 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
230000002175 menstrual effect Effects 0.000 claims description 2
208000030159 metabolic disease Diseases 0.000 claims description 2
230000037323 metabolic rate Effects 0.000 claims description 2
208000004296 neuralgia Diseases 0.000 claims description 2
208000021722 neuropathic pain Diseases 0.000 claims description 2
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
201000008482 osteoarthritis Diseases 0.000 claims description 2
230000036961 partial effect Effects 0.000 claims description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
150000004714 phosphonium salts Chemical class 0.000 claims description 2
231100000872 sexual dysfunction Toxicity 0.000 claims description 2
230000005586 smoking cessation Effects 0.000 claims description 2
230000007103 stamina Effects 0.000 claims description 2
230000035924 thermogenesis Effects 0.000 claims description 2
SPTOSPOJHYMLCB-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-2-methylbut-3-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C(C=C)C)=CSC2=C1 SPTOSPOJHYMLCB-UHFFFAOYSA-N 0.000 claims 2
DISWDTIMRONVJU-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-2-methylpropan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C(C)C)=CSC2=C1 DISWDTIMRONVJU-UHFFFAOYSA-N 0.000 claims 2
YJUSYDAVVNRRJA-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-2-yn-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)C#CC)=CSC2=C1 YJUSYDAVVNRRJA-UHFFFAOYSA-N 0.000 claims 2
RRIAMYOMYITSMB-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]prop-2-en-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C=C)O)=CSC2=C1 RRIAMYOMYITSMB-UHFFFAOYSA-N 0.000 claims 2
BMJCWHAYLOAJSO-UHFFFAOYSA-N 2-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]propan-2-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(C)(O)C)=CSC2=C1 BMJCWHAYLOAJSO-UHFFFAOYSA-N 0.000 claims 2
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
229940100198 alkylating agent Drugs 0.000 claims 2
239000002168 alkylating agent Substances 0.000 claims 2
210000000941 bile Anatomy 0.000 claims 2
239000004575 stone Substances 0.000 claims 2
206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
208000001953 Hypotension Diseases 0.000 claims 1
206010021639 Incontinence Diseases 0.000 claims 1
208000003028 Stuttering Diseases 0.000 claims 1
YMWUVSMEXTWYSB-UHFFFAOYSA-N [3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methanol Chemical compound C12=CC(SC)=CC=C2SC=C1C1=C(CO)SC2=NCCN12 YMWUVSMEXTWYSB-UHFFFAOYSA-N 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
230000036543 hypotension Effects 0.000 claims 1
210000003405 ileum Anatomy 0.000 claims 1
230000003387 muscular Effects 0.000 claims 1
229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
238000009120 supportive therapy Methods 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
210000001635 urinary tract Anatomy 0.000 claims 1
229940124535 smoking cessation aid Drugs 0.000 abstract description 2
206010004716 Binge eating Diseases 0.000 abstract 1
230000006399 behavior Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 222
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 127
239000007787 solid Substances 0.000 description 120
239000000243 solution Substances 0.000 description 120
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 101
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 95
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 74
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 63
239000000047 product Substances 0.000 description 63
235000002639 sodium chloride Nutrition 0.000 description 57
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 50
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
229920006395 saturated elastomer Polymers 0.000 description 40
239000011780 sodium chloride Substances 0.000 description 37
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 33
239000000284 extract Substances 0.000 description 30
239000000377 silicon dioxide Substances 0.000 description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
238000003818 flash chromatography Methods 0.000 description 29
239000000725 suspension Substances 0.000 description 28
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
238000000746 purification Methods 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000011734 sodium Substances 0.000 description 20
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
239000003826 tablet Substances 0.000 description 18
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 17
239000012312 sodium hydride Substances 0.000 description 17
229910000104 sodium hydride Inorganic materials 0.000 description 17
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 16
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 15
239000003446 ligand Substances 0.000 description 15
239000012299 nitrogen atmosphere Substances 0.000 description 15
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 14
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 14
229910052794 bromium Inorganic materials 0.000 description 14
230000027455 binding Effects 0.000 description 13
229910052757 nitrogen Inorganic materials 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
241000700159 Rattus Species 0.000 description 12
239000012074 organic phase Substances 0.000 description 12
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 11
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 11
239000002585 base Substances 0.000 description 11
239000000872 buffer Substances 0.000 description 11
239000006185 dispersion Substances 0.000 description 11
239000003480 eluent Substances 0.000 description 11
239000002480 mineral oil Substances 0.000 description 11
235000010446 mineral oil Nutrition 0.000 description 11
238000003556 assay Methods 0.000 description 10
YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 10
239000012279 sodium borohydride Substances 0.000 description 10
229910000033 sodium borohydride Inorganic materials 0.000 description 10
238000003756 stirring Methods 0.000 description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
239000002775 capsule Substances 0.000 description 9
239000000460 chlorine Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
229910052943 magnesium sulfate Inorganic materials 0.000 description 9
235000019341 magnesium sulphate Nutrition 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000012071 phase Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
BKCZXQQTZPBRPV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=CSC=4N3CCN=4)=CSC2=C1 BKCZXQQTZPBRPV-UHFFFAOYSA-N 0.000 description 8
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
229910052801 chlorine Inorganic materials 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
239000008188 pellet Substances 0.000 description 8
239000001103 potassium chloride Substances 0.000 description 8
235000011164 potassium chloride Nutrition 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
235000013305 food Nutrition 0.000 description 7
239000001530 fumaric acid Substances 0.000 description 7
230000009871 nonspecific binding Effects 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
230000009870 specific binding Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
235000019270 ammonium chloride Nutrition 0.000 description 6
239000012530 fluid Substances 0.000 description 6
230000037406 food intake Effects 0.000 description 6
235000012631 food intake Nutrition 0.000 description 6
238000001802 infusion Methods 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 6
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 5
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 5
238000009505 enteric coating Methods 0.000 description 5
239000002702 enteric coating Substances 0.000 description 5
150000002170 ethers Chemical class 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229960002748 norepinephrine Drugs 0.000 description 5
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000012258 stirred mixture Substances 0.000 description 5
125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 4
SKEHLMSOHHQWIY-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-bromo-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=C(SC4=NCCN43)Br)=CSC2=C1 SKEHLMSOHHQWIY-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
210000005013 brain tissue Anatomy 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
239000012265 solid product Substances 0.000 description 4
239000012453 solvate Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
238000005303 weighing Methods 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
241000400611 Eucalyptus deanei Species 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
102000010909 Monoamine Oxidase Human genes 0.000 description 3
108010062431 Monoamine oxidase Proteins 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229940081734 cellulose acetate phthalate Drugs 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000010908 decantation Methods 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
239000008172 hydrogenated vegetable oil Substances 0.000 description 3
235000011147 magnesium chloride Nutrition 0.000 description 3
229960002337 magnesium chloride Drugs 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
239000002609 medium Substances 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
IBXYFQYYVRYALP-UHFFFAOYSA-N molport-003-926-405 Chemical compound Cl[I-](Cl)(Cl)Cl.C[N+](C)(C)CC1=CC=CC=C1 IBXYFQYYVRYALP-UHFFFAOYSA-N 0.000 description 3
230000000407 monoamine reuptake Effects 0.000 description 3
230000000966 norepinephrine reuptake Effects 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
WTUVGNVEQDDTCM-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-2-bromo-3-phenylmethoxypropan-1-one Chemical compound C=1SC2=CC=CC=C2C=1C(=O)C(Br)COCC1=CC=CC=C1 WTUVGNVEQDDTCM-UHFFFAOYSA-N 0.000 description 2
VLWUPJUWLHHZIS-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-(dimethylamino)propan-1-one;hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)CCN(C)C)=CSC2=C1 VLWUPJUWLHHZIS-UHFFFAOYSA-N 0.000 description 2
LBPFBKVAFCBVLQ-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-phenylmethoxypropan-1-one Chemical compound C=1SC2=CC=CC=C2C=1C(=O)CCOCC1=CC=CC=C1 LBPFBKVAFCBVLQ-UHFFFAOYSA-N 0.000 description 2
ZTTZKDDWXHQKSY-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)ethanone Chemical compound C1=CC=C2C(C(=O)C)=CSC2=C1 ZTTZKDDWXHQKSY-UHFFFAOYSA-N 0.000 description 2
LJMBFEBDZAOKTD-UHFFFAOYSA-N 1-(7-methoxy-1-benzothiophen-3-yl)ethanone Chemical compound COC1=CC=CC2=C1SC=C2C(C)=O LJMBFEBDZAOKTD-UHFFFAOYSA-N 0.000 description 2
QPIGXGXRDGXIOR-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]-n-propan-2-ylmethanimine Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=NC(C)C)=CSC2=C1 QPIGXGXRDGXIOR-UHFFFAOYSA-N 0.000 description 2
WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
WFWNTLYUEWAQJX-UHFFFAOYSA-N 1-methoxy-2-(4-phenoxybut-2-ynylsulfanyl)benzene Chemical compound COC1=CC=CC=C1SCC#CCOC1=CC=CC=C1 WFWNTLYUEWAQJX-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
UVUFMJALNDDZOD-UHFFFAOYSA-N 2-bromo-3-(5-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(OC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 UVUFMJALNDDZOD-UHFFFAOYSA-N 0.000 description 2
AIUSKKULSAQPEB-UHFFFAOYSA-N 2-bromo-3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C12=CC(SC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 AIUSKKULSAQPEB-UHFFFAOYSA-N 0.000 description 2
YZOGROCAAWYRBU-UHFFFAOYSA-N 2-cyclopropyl-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CC1CC1 YZOGROCAAWYRBU-UHFFFAOYSA-N 0.000 description 2
IALGRRFZGRXFKT-UHFFFAOYSA-N 2-cyclopropylacetyl chloride Chemical compound ClC(=O)CC1CC1 IALGRRFZGRXFKT-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
MAZXGTVVVRCULB-UHFFFAOYSA-N 3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=O)=COC2=C1 MAZXGTVVVRCULB-UHFFFAOYSA-N 0.000 description 2
OREBWIBJEFJQTB-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(cyclobutylmethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C=1SC2=CC=CC=C2C=1C=1N2CCN=C2SC=1COCC1CCC1 OREBWIBJEFJQTB-UHFFFAOYSA-N 0.000 description 2
INQWVSNWKLOUDT-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-methylsulfanyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)SC)=CSC2=C1 INQWVSNWKLOUDT-UHFFFAOYSA-N 0.000 description 2
UZUUVNIERLVVCH-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=CSC=4N3CCN=4)=CSC2=C1 UZUUVNIERLVVCH-UHFFFAOYSA-N 0.000 description 2
KFGPZSUBOWPPMR-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=CC=C2C(C3=CSC4=NCCCN43)=CSC2=C1 KFGPZSUBOWPPMR-UHFFFAOYSA-N 0.000 description 2
SRYQCAVJRROBBI-UHFFFAOYSA-N 3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=CSC2=NCCN12 SRYQCAVJRROBBI-UHFFFAOYSA-N 0.000 description 2
QDYLPKSLKVRTAC-UHFFFAOYSA-N 3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carbaldehyde Chemical compound C12=CC(SC)=CC=C2SC=C1C1=C(C=O)SC2=NCCN12 QDYLPKSLKVRTAC-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
FDTMBOBAMHPBJB-UHFFFAOYSA-N Br.COc1cccc2c(csc12)C1=CSC2=NCCN12 Chemical compound Br.COc1cccc2c(csc12)C1=CSC2=NCCN12 FDTMBOBAMHPBJB-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
244000303965 Cyamopsis psoralioides Species 0.000 description 2
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
LZCOQTDXKCNBEE-XJMZPCNVSA-N N-methylscopolamine Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-XJMZPCNVSA-N 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
206010040108 Serotonin syndrome Diseases 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
YXXVEUFXNANKJA-UHFFFAOYSA-M [3-(1-benzothiophen-3-yl)-3-oxopropyl]-trimethylazanium iodide Chemical compound [I-].C[N+](C)(C)CCC(=O)c1csc2ccccc12 YXXVEUFXNANKJA-UHFFFAOYSA-M 0.000 description 2
JBFAFQDHPBMWJR-UHFFFAOYSA-N [3-(1-benzothiophen-3-yl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidin-2-yl]methanol Chemical compound C1=CC=C2C(C3=C(SC4=NCCCN43)CO)=CSC2=C1 JBFAFQDHPBMWJR-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000001351 alkyl iodides Chemical class 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
230000031709 bromination Effects 0.000 description 2
238000005893 bromination reaction Methods 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
WHNPUKSXIKNEMZ-UHFFFAOYSA-N ethyl 3-(1-benzothiophen-3-yl)-2-bromo-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)C(Br)C(=O)OCC)=CSC2=C1 WHNPUKSXIKNEMZ-UHFFFAOYSA-N 0.000 description 2
ZJMVBGLGQKBNAJ-UHFFFAOYSA-N ethyl 3-(1-benzothiophen-3-yl)-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)CC(=O)OCC)=CSC2=C1 ZJMVBGLGQKBNAJ-UHFFFAOYSA-N 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000007943 implant Substances 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000006201 parenteral dosage form Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
229960004274 stearic acid Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
150000003557 thiazoles Chemical class 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000001665 trituration Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
RAQPZQAQMHUKTB-TYYBGVCCSA-N (e)-but-2-enedioic acid;methanol Chemical compound OC.OC(=O)\C=C\C(O)=O RAQPZQAQMHUKTB-TYYBGVCCSA-N 0.000 description 1
SQDDGOVNJMIFFT-UHFFFAOYSA-N 1,1-bis(diethoxyphosphoryl)-n,n-dimethylmethanamine Chemical compound CCOP(=O)(OCC)C(N(C)C)P(=O)(OCC)OCC SQDDGOVNJMIFFT-UHFFFAOYSA-N 0.000 description 1
ZIRGWUZHKJDYKT-UHFFFAOYSA-N 1,3-thiazole-2-carbonitrile Chemical compound N#CC1=NC=CS1 ZIRGWUZHKJDYKT-UHFFFAOYSA-N 0.000 description 1
LSVDHPXBWPECCJ-UHFFFAOYSA-N 1-(7-methoxy-2,3-dihydro-1-benzothiophen-3-yl)-2-phenoxyethanone Chemical compound C1SC=2C(OC)=CC=CC=2C1C(=O)COC1=CC=CC=C1 LSVDHPXBWPECCJ-UHFFFAOYSA-N 0.000 description 1
JAJUKPBMFIUECL-UHFFFAOYSA-N 1-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]butan-1-ol Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C(O)CCC)=CSC2=C1 JAJUKPBMFIUECL-UHFFFAOYSA-N 0.000 description 1
UOWIYNWMROWVDG-UHFFFAOYSA-N 1-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(C)=O UOWIYNWMROWVDG-UHFFFAOYSA-N 0.000 description 1
XFUMHENRNCUHOH-UHFFFAOYSA-N 1-fluoro-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(F)C=C1 XFUMHENRNCUHOH-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
DSCJETUEDFKYGN-UHFFFAOYSA-N 2-Methoxybenzenethiol Chemical compound COC1=CC=CC=C1S DSCJETUEDFKYGN-UHFFFAOYSA-N 0.000 description 1
MIMUGAJISMFUGL-UHFFFAOYSA-N 2-bromo-3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(SC)=CC=C2SC=C1C1=C(Br)SC2=NCCN12 MIMUGAJISMFUGL-UHFFFAOYSA-N 0.000 description 1
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
QKEKNNARIRBOMF-UHFFFAOYSA-N 2-fluoro-5-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(F)C(C=O)=C1 QKEKNNARIRBOMF-UHFFFAOYSA-N 0.000 description 1
IQTAGLNYWZMGGX-UHFFFAOYSA-N 3-(1-benzofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2OC(C3=CSC=4N3CCN=4)=CC2=C1 IQTAGLNYWZMGGX-UHFFFAOYSA-N 0.000 description 1
IPZFRXRLIVTZIX-UHFFFAOYSA-N 3-(1-benzofuran-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=CSC=4N3CCN=4)=COC2=C1 IPZFRXRLIVTZIX-UHFFFAOYSA-N 0.000 description 1
ADZWOMLAMVQBBK-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(2-methylprop-2-enyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)CC(=C)C)=CSC2=C1 ADZWOMLAMVQBBK-UHFFFAOYSA-N 0.000 description 1
UARZGTRHSJQGFS-WLHGVMLRSA-N 3-(1-benzothiophen-3-yl)-2-(2-methylprop-2-enyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.c1cccc2c1scc2C1=C(CC(=C)C)SC2=NCCN21 UARZGTRHSJQGFS-WLHGVMLRSA-N 0.000 description 1
LHFVBSDXXYATRZ-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(cyclopropylmethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C=1SC2=CC=CC=C2C=1C=1N2CCN=C2SC=1COCC1CC1 LHFVBSDXXYATRZ-UHFFFAOYSA-N 0.000 description 1
BIOUJAYKDDMMKR-WLHGVMLRSA-N 3-(1-benzothiophen-3-yl)-2-(cyclopropylmethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C=1SC2=CC=CC=C2C=1C=1N2CCN=C2SC=1COCC1CC1 BIOUJAYKDDMMKR-WLHGVMLRSA-N 0.000 description 1
OLMGCVNDAHKFMQ-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-(ethoxymethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC=C2C(C3=C(SC4=NCCN43)COCC)=CSC2=C1 OLMGCVNDAHKFMQ-UHFFFAOYSA-N 0.000 description 1
PIXLGCUCZSILKS-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-cyclopropyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1CC1C(S1)=C(C=2C3=CC=CC=C3SC=2)N2C1=NCC2 PIXLGCUCZSILKS-UHFFFAOYSA-N 0.000 description 1
VVDZEYDXPTXINV-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-cyclopropyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1CC1C(S1)=C(C=2C3=CC=CC=C3SC=2)N2C1=NCC2 VVDZEYDXPTXINV-UHFFFAOYSA-N 0.000 description 1
DIAXOIUUEQVSOK-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-2-iodo-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrochloride Chemical compound Cl.C1=CC=C2C(C3=C(SC4=NCCN43)I)=CSC2=C1 DIAXOIUUEQVSOK-UHFFFAOYSA-N 0.000 description 1
HGVYKIRNOKICFM-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carboxylic acid Chemical compound C1CN2C(=C(SC2=N1)C(=O)O)C3=CSC4=CC=CC=C43 HGVYKIRNOKICFM-UHFFFAOYSA-N 0.000 description 1
CASSLFVBWWLKPI-UHFFFAOYSA-N 3-(1-benzothiophen-3-yl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine-2-carbaldehyde Chemical compound C1=CC=C2C(C3=C(SC4=NCCCN43)C=O)=CSC2=C1 CASSLFVBWWLKPI-UHFFFAOYSA-N 0.000 description 1
ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 1
GMPXFKLYBVWGLP-UHFFFAOYSA-N 3-(5-methoxy-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(OC)=CC=C2SC=C1C1=CSC2=NCCN12 GMPXFKLYBVWGLP-UHFFFAOYSA-N 0.000 description 1
HJWYKXQANGRSIE-UHFFFAOYSA-N 3-(5-methylsulfanyl-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C12=CC(SC)=CC=C2SC=C1C1=CSC2=NCCN12 HJWYKXQANGRSIE-UHFFFAOYSA-N 0.000 description 1
SRWDQSRTOOMPMO-UHFFFAOYSA-N 3-bromo-1-benzothiophene Chemical compound C1=CC=C2C(Br)=CSC2=C1 SRWDQSRTOOMPMO-UHFFFAOYSA-N 0.000 description 1
USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
PDCDSOFPOAMRQU-UHFFFAOYSA-N 3-methylsulfanyl-1-benzothiophene-2-carboxylic acid Chemical compound CSc1c(sc2ccccc12)C(O)=O PDCDSOFPOAMRQU-UHFFFAOYSA-N 0.000 description 1
IDEODNHVORFHQO-UHFFFAOYSA-N 4-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]but-3-en-2-one Chemical compound C1=CC=C2C(C3=C(SC4=NCCN43)C=CC(=O)C)=CSC2=C1 IDEODNHVORFHQO-UHFFFAOYSA-N 0.000 description 1
ZEVUHRJDTWDODR-UHFFFAOYSA-N 4-chlorobut-2-ynoxybenzene Chemical compound ClCC#CCOC1=CC=CC=C1 ZEVUHRJDTWDODR-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
PMZJSVBYQJFOQA-UHFFFAOYSA-N 5-methylsulfanyl-1-benzothiophene Chemical compound CSC1=CC=C2SC=CC2=C1 PMZJSVBYQJFOQA-UHFFFAOYSA-N 0.000 description 1
NZVFVVMOZAWNTM-UHFFFAOYSA-N 5-methylsulfanyl-1-benzothiophene-2-carboxylic acid Chemical compound CSC1=CC=C2SC(C(O)=O)=CC2=C1 NZVFVVMOZAWNTM-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 1
101710185917 Amine oxidase [flavin-containing] A Proteins 0.000 description 1
HRJNDJQHIYBUNK-UHFFFAOYSA-N Br.COc1cccc2c(csc12)C1=C(Br)SC2=NCCN12 Chemical compound Br.COc1cccc2c(csc12)C1=C(Br)SC2=NCCN12 HRJNDJQHIYBUNK-UHFFFAOYSA-N 0.000 description 1
NLFVQLRHUHFOTM-UHFFFAOYSA-N CCOBrOC Chemical compound CCOBrOC NLFVQLRHUHFOTM-UHFFFAOYSA-N 0.000 description 1
FLAKGKCBSLMHQU-UHFFFAOYSA-N CC[Mg] Chemical compound CC[Mg] FLAKGKCBSLMHQU-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
NECFGSDKKIGJNO-UHFFFAOYSA-N Cl.OCC1=C(N2CCN=C2S1)c1csc2ccccc12 Chemical compound Cl.OCC1=C(N2CCN=C2S1)c1csc2ccccc12 NECFGSDKKIGJNO-UHFFFAOYSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
241000506654 Haemulon album Species 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
RNXYXIKLWRRZNU-UHFFFAOYSA-N Kynuramine Natural products NCCCC(=O)C1=CC=CC=N1 RNXYXIKLWRRZNU-UHFFFAOYSA-N 0.000 description 1
239000002211 L-ascorbic acid Substances 0.000 description 1
235000000069 L-ascorbic acid Nutrition 0.000 description 1
101150051213 MAOA gene Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 description 1
OTVQDZVMUBSAPX-UHFFFAOYSA-N [3-(5-chloro-1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]methyl formate Chemical compound C12=CC(Cl)=CC=C2SC=C1C1=C(COC=O)SC2=NCCN12 OTVQDZVMUBSAPX-UHFFFAOYSA-N 0.000 description 1
GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000003113 alkalizing effect Effects 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005038 alkynylalkyl group Chemical group 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005002 aryl methyl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 1
WOFIDTFNJZRJRE-UHFFFAOYSA-N but-3-en-2-ol Chemical compound [CH2]C(O)C=C WOFIDTFNJZRJRE-UHFFFAOYSA-N 0.000 description 1
FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
AIPRAPZUGUTQKX-UHFFFAOYSA-N diethoxyphosphorylmethylbenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1 AIPRAPZUGUTQKX-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
PFKVAWRUKCXZFI-UHFFFAOYSA-N ethoxy-methoxy-propan-2-yloxy-lambda3-bromane Chemical compound COBr(OC(C)C)OCC PFKVAWRUKCXZFI-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
PEZHFEMIFKAXAV-UHFFFAOYSA-N ethyl 2-[3-(1-benzothiophen-3-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]acetate oxalic acid Chemical compound C(C(=O)O)(=O)O.S1C2=C(C(=C1)C=1N3C(SC1CC(=O)OCC)=NCC3)C=CC=C2 PEZHFEMIFKAXAV-UHFFFAOYSA-N 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
125000004446 heteroarylalkyl group Chemical group 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
150000002462 imidazolines Chemical class 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
QLPVTIQQFGWSQQ-UHFFFAOYSA-N kynuramine Chemical compound NCCC(=O)C1=CC=CC=C1N QLPVTIQQFGWSQQ-UHFFFAOYSA-N 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 description 1
FCPRDUXJWIUVPZ-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=CC=[C-]1 FCPRDUXJWIUVPZ-UHFFFAOYSA-M 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
QBNOPZJAURRQCE-UHFFFAOYSA-M magnesium;prop-1-yne;bromide Chemical compound [Mg+2].[Br-].CC#[C-] QBNOPZJAURRQCE-UHFFFAOYSA-M 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940087646 methanolamine Drugs 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
APROLTTVXDETFR-UHFFFAOYSA-N methylsulfanyl 1-benzothiophene-2-carboxylate Chemical compound S1C2=C(C=C1C(=O)OSC)C=CC=C2 APROLTTVXDETFR-UHFFFAOYSA-N 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
MKUWVMRNQOOSAT-UHFFFAOYSA-N methylvinylmethanol Natural products CC(O)C=C MKUWVMRNQOOSAT-UHFFFAOYSA-N 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000003801 milling Methods 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
OYVXVLSZQHSNDK-UHFFFAOYSA-N n-methoxy-n-methylacetamide Chemical compound CON(C)C(C)=O OYVXVLSZQHSNDK-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
239000006072 paste Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000005375 photometry Methods 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
PUGUQINMNYINPK-UHFFFAOYSA-N tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CCl)CC1 PUGUQINMNYINPK-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
UPVCRZBVVOXMDA-UHFFFAOYSA-N trimethylazanium;formate Chemical compound OC=O.CN(C)C UPVCRZBVVOXMDA-UHFFFAOYSA-N 0.000 description 1
ZNEOHLHCKGUAEB-UHFFFAOYSA-N trimethylphenylammonium Chemical compound C[N+](C)(C)C1=CC=CC=C1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000001521 two-tailed test Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)

SK1685-2001A 1999-05-21 2000-05-11 Tiazolové deriváty a farmaceutické kompozície ich obsahujúce SK16852001A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9911863.0A GB9911863D0 (en)	1999-05-21	1999-05-21	Therapeutic agents
PCT/EP2000/004279 WO2000071549A1 (fr)	1999-05-21	2000-05-11	Derives de thiazole et compositions pharmaceutiques contenant ces derives

Publications (1)

Publication Number	Publication Date
SK16852001A3 true SK16852001A3 (sk)	2002-05-09

Family

ID=10853913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1685-2001A SK16852001A3 (sk)	1999-05-21	2000-05-11	Tiazolové deriváty a farmaceutické kompozície ich obsahujúce

Country Status (19)

Country	Link
EP (1)	EP1178993A1 (fr)
JP (1)	JP2003500410A (fr)
KR (1)	KR20020033626A (fr)
CN (1)	CN1361783A (fr)
AU (1)	AU5065700A (fr)
BG (1)	BG106227A (fr)
BR (1)	BR0010827A (fr)
CA (1)	CA2374926A1 (fr)
CZ (1)	CZ20014171A3 (fr)
GB (1)	GB9911863D0 (fr)
HU (1)	HUP0201376A2 (fr)
IL (1)	IL146540A0 (fr)
MX (1)	MXPA01011895A (fr)
NO (1)	NO20015667L (fr)
PL (1)	PL352282A1 (fr)
SK (1)	SK16852001A3 (fr)
TR (1)	TR200200164T2 (fr)
WO (1)	WO2000071549A1 (fr)
ZA (1)	ZA200110022B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0005789D0 (en) *	2000-03-11	2000-05-03	Knoll Ag	Therapeutic agents
GB0023610D0 (en) *	2000-09-27	2000-11-08	Knoll Ag	Therapeutic agents
UA76130C2 (en) *	2000-11-20	2006-07-17	Merck Patent Gmbh	Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
JP2005501861A (ja)	2001-08-22	2005-01-20	アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	１，４−ベンゾチエピン１，１−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
US6884812B2 (en)	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7399777B2 (en)	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
PL208515B1 (pl)	2001-08-31	2011-05-31	Sanofi Aventis Deutschland	Pochodne diarylocykloalkilowe, środki lecznicze zawierające te związki oraz ich zastosowanie jako aktywatorów PPAR
US7078404B2 (en)	2002-04-11	2006-07-18	Sanofi-Aventis Deutschland Gmbh	Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7223796B2 (en)	2002-04-11	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en)	2002-06-07	2006-05-23	Aventis Pharma Deutschland Gmbh	N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en)	2002-07-11	2007-08-28	Sanofi-Aventis Deutschland Gmbh	Urea- and urethane-substituted acylureas, process for their preparation and their use
KR20050025345A (ko)	2002-07-12	2005-03-14	아벤티스 파마 도이칠란트 게엠베하	헤테로사이클릭으로 치환된 벤조일우레아, 이들의제조방법 및 약제로서 이의 용도
US20040157922A1 (en)	2002-10-04	2004-08-12	Aventis Pharma Deutschland Gmbh	Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en)	2002-10-12	2007-04-24	Sanofi-Aventis Deutschland Gmbh	Bicyclic inhibitors of hormone sensitive lipase
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US20040242583A1 (en)	2003-01-20	2004-12-02	Aventis Pharma Deutschland Gmbh	Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en)	2003-01-23	2007-02-20	Sanofi-Aventis Deutschland Gmbh	Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7196114B2 (en)	2003-02-17	2007-03-27	Sanofi-Aventis Deutschland Gmbh	Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7501440B2 (en)	2003-03-07	2009-03-10	Sanofi-Aventis Deutschland Gmbh	Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10314610A1 (de)	2003-04-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7094800B2 (en)	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en)	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en)	2003-07-28	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de)	2003-08-01	2005-02-03	Aventis Pharma Deutschland Gmbh	Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
US7241787B2 (en)	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7498341B2 (en)	2004-01-31	2009-03-03	Sanofi Aventis Deutschland Gmbh	Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en)	2004-01-31	2008-12-30	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en)	2004-01-31	2008-07-22	Sanofi-Aventis Deutschland Gmbh,	7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de)	2004-02-02	2005-08-18	Aventis Pharma Deutschland Gmbh	Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE602004004631D1 (de)	2004-04-01	2007-03-22	Sanofi Aventis Deutschland	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
ES2427247T3 (es)	2006-03-13	2013-10-30	Kyorin Pharmaceutical Co., Ltd.	Aminoquinolonas como inhibidores de GSK-3
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
DE102007002260A1 (de)	2007-01-16	2008-07-31	Sanofi-Aventis	Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
CN101855228B (zh)	2007-09-11	2012-10-24	杏林制药株式会社	作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
CN102344457B (zh)	2007-09-12	2015-07-22	杏林制药株式会社	作为 gsk-3 抑制剂的螺环状氨基喹诺酮
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US9833240B2 (en)	2008-02-18	2017-12-05	Covidien Lp	Lock bar spring and clip for implant deployment device
US8758373B2 (en)	2008-02-18	2014-06-24	Covidien Lp	Means and method for reversibly connecting a patch to a patch deployment device
US9301826B2 (en)	2008-02-18	2016-04-05	Covidien Lp	Lock bar spring and clip for implant deployment device
US9398944B2 (en)	2008-02-18	2016-07-26	Covidien Lp	Lock bar spring and clip for implant deployment device
WO2009104182A2 (fr)	2008-02-18	2009-08-27	Polytouch Medical Ltd	Dispositif et procédé pour déployer et faire tenir une pièce sur un tissu biologique
US9034002B2 (en)	2008-02-18	2015-05-19	Covidien Lp	Lock bar spring and clip for implant deployment device
US8808314B2 (en)	2008-02-18	2014-08-19	Covidien Lp	Device and method for deploying and attaching an implant to a biological tissue
US9393002B2 (en)	2008-02-18	2016-07-19	Covidien Lp	Clip for implant deployment device
US9044235B2 (en)	2008-02-18	2015-06-02	Covidien Lp	Magnetic clip for implant deployment device
US8317808B2 (en)	2008-02-18	2012-11-27	Covidien Lp	Device and method for rolling and inserting a prosthetic patch into a body cavity
US9393093B2 (en)	2008-02-18	2016-07-19	Covidien Lp	Clip for implant deployment device
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
EP2485747A4 (fr) *	2008-06-21	2013-10-23	Kenneth Blum	Personnalisation dirigée par l'adn des composés analgesiques comme modalité thérapeutique
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2792307B1 (fr)	2008-10-20	2017-10-04	Covidien LP	Dispositif pour fixer une pièce sur un tissu biologique
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CN102421784B (zh)	2009-03-11	2015-09-30	杏林制药株式会社	作为gsk-3抑制剂的7-环烷基氨基喹诺酮
WO2011021082A1 (fr)	2009-08-17	2011-02-24	PolyTouch Medical, Inc.	Moyen et procédé pour relier de manière réversible un implant à un dispositif de déploiement
WO2011021083A1 (fr)	2009-08-17	2011-02-24	PolyTouch Medical, Inc.	Dispositif de déploiement de pièce articulée et procédé d'utilisation
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
CA2774903A1 (fr)	2009-10-02	2011-04-07	Sanofi	Utilisation de composes a activite inhibitrice de sglt-1/sglt-2 pour produire des medicaments pour le traitement de maladies osseuses
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (fr)	2011-03-08	2014-12-24	Sanofi	Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120050A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683705B1 (fr)	2011-03-08	2015-04-22	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
CN114113064B (zh) *	2021-12-27	2023-09-08	郑州大学	基于苯并双噻唑的光响应类氧化物酶及其制备方法和在比色检测食品中谷胱甘肽的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9513467D0 (en) *	1995-07-01	1995-09-06	Knoll Ag	Therapeutic agents
GB9705428D0 (en) *	1997-03-15	1997-04-30	Knoll Ag	Therapeutic agents

1999
- 1999-05-21 GB GBGB9911863.0A patent/GB9911863D0/en not_active Ceased
2000
- 2000-05-11 JP JP2000619805A patent/JP2003500410A/ja not_active Withdrawn
- 2000-05-11 BR BR0010827-8A patent/BR0010827A/pt not_active IP Right Cessation
- 2000-05-11 CZ CZ20014171A patent/CZ20014171A3/cs unknown
- 2000-05-11 TR TR2002/00164T patent/TR200200164T2/xx unknown
- 2000-05-11 WO PCT/EP2000/004279 patent/WO2000071549A1/fr not_active Ceased
- 2000-05-11 HU HU0201376A patent/HUP0201376A2/hu unknown
- 2000-05-11 EP EP00935009A patent/EP1178993A1/fr not_active Withdrawn
- 2000-05-11 CN CN00810653A patent/CN1361783A/zh active Pending
- 2000-05-11 IL IL14654000A patent/IL146540A0/xx unknown
- 2000-05-11 KR KR1020017014892A patent/KR20020033626A/ko not_active Withdrawn
- 2000-05-11 MX MXPA01011895A patent/MXPA01011895A/es unknown
- 2000-05-11 CA CA002374926A patent/CA2374926A1/fr not_active Abandoned
- 2000-05-11 AU AU50657/00A patent/AU5065700A/en not_active Abandoned
- 2000-05-11 PL PL00352282A patent/PL352282A1/xx not_active Application Discontinuation
- 2000-05-11 SK SK1685-2001A patent/SK16852001A3/sk unknown
2001
- 2001-11-20 NO NO20015667A patent/NO20015667L/no not_active Application Discontinuation
- 2001-12-05 ZA ZA200110022A patent/ZA200110022B/xx unknown
- 2001-12-17 BG BG106227A patent/BG106227A/xx unknown

Also Published As

Publication number	Publication date
CZ20014171A3 (cs)	2002-06-12
JP2003500410A (ja)	2003-01-07
PL352282A1 (en)	2003-08-11
EP1178993A1 (fr)	2002-02-13
WO2000071549A1 (fr)	2000-11-30
NO20015667L (no)	2002-01-21
GB9911863D0 (en)	1999-07-21
BR0010827A (pt)	2002-06-04
NO20015667D0 (no)	2001-11-20
IL146540A0 (en)	2002-07-25
ZA200110022B (en)	2003-05-28
CA2374926A1 (fr)	2000-11-30
CN1361783A (zh)	2002-07-31
HUP0201376A2 (en)	2002-08-28
MXPA01011895A (es)	2004-03-19
AU5065700A (en)	2000-12-12
KR20020033626A (ko)	2002-05-07
TR200200164T2 (tr)	2002-04-22
BG106227A (en)	2002-08-30

Publication	Publication Date	Title
SK16852001A3 (sk)	2002-05-09	Tiazolové deriváty a farmaceutické kompozície ich obsahujúce
EP0970090B1 (fr)	2002-06-05	4-arylmethylene-2-imino-2,3-dihydrothiazoles substitues, leurs derives, et leur utilisation pharmaceutique
US6900216B2 (en)	2005-05-31	Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents
SK16842001A3 (sk)	2002-04-04	Substituované imidazotiazoly ako antidepresívne prostriedky
WO2002026747A1 (fr)	2002-04-04	Derives de dihydroimidazo[2,1-b]thiazole et de dihydro-5h-thiazolo[3,2-a]pyrimidine possedant une affinite pour les recepteurs 5-ht
US5869492A (en)	1999-02-09	Condensed thiazole derivatives, having 5-HT receptor affinity
KR100826304B1 (ko)	2008-04-29	피롤로[2,1-ｂ][1,3]벤조티아제핀 및 정신병 치료 활성을갖는 약제의 제조를 위한 그의 용도
CZ9903260A3 (cs)	2000-11-15	Terapeutická činidla
MXPA97009509A (en)	1998-10-15	Therapeutic agents